A ranar 27 ga Satumba, gidan yanar gizon hukuma na CDE ya nuna cewa an karɓi aikace-aikacen sabon nuni na Pfize Crisaborole cream (sunan kasuwancin China: Sultanming, Sunan kasuwanci na Ingilishi: Eucris a, Staquis), mai yiwuwa ga yara da manya masu shekaru 3 watanni da mazan atopic dermatitis marasa lafiya.

Crisaborole wani ƙananan ƙwayoyin cuta ne, ba na hormonal ba, mai hana ƙwayoyin cuta na phosphodiesterase 4 (PDE-4) wanda Anacor ya haɓaka.A watan Mayun 2016, Pfizer ya sayi kamfanin akan dala biliyan 5.2 kuma ya sami maganin.A cikin Disamba na wannan shekarar, FDA ta amince da Crisaborole don tallace-tallace, ya zama magani na farko na magani don maganin dermatitis da aka amince da shi a cikin shekaru 10, kuma na farko da magungunan waje marasa steroidal don hana fata PDE4.

Abubuwan da ke hana su sabuwa a matsayin sabon magani, a zahiri, baka na baka na kwastomomi masu tsauri da kuma amanar haushi, babu wani takin gargajiya.

Crisaborole a matsayin magungunan Topical, ƙarancin shiga cikin fata, yiwuwar wannan sakamako na gefen rashin jin daɗi na gastrointestinal kuma an rage shi zuwa ƙananan ƙananan.

A sakamakon haka, Crisaborole ba zato ba tsammani ya zama "bege na dukan ƙauyen" tun shekaru 15, likitoci da iyaye sun yi sha'awar samun aminci, tasiri da kuma dogon lokaci na amfani da magungunan ƙwayoyi yana da tsawo.

Yaya tasiri ne miyagun ƙwayoyi tare da Crisaborole?

A cikin 2016, binciken gwaji na gwaji na biyu na Phase III ya kawo labarai masu ban sha'awa sosai, Crisaborole, maganin shafawa na masu hana phosphodiesterase-4 (PDE4), ga marasa lafiya da cututtukan cututtukan fata fiye da shekaru 2 (yara da manya), sun sami sakamako mai kyau na asibiti.